Peer review reports
From: Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models
Original Submission |
10 Feb 2022 |
Submitted |
Original manuscript
|
Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
Resubmission - Version 3 |
|
Submitted |
Manuscript version 3
|
5 Apr 2022 |
Reviewed |
Reviewer Report
|
27 Apr 2022 |
Reviewed |
Reviewer Report
|
17 May 2022 |
Author responded |
Author comments - Yifan Zhai
|
Resubmission - Version 4 |
17 May 2022 |
Submitted |
Manuscript version 4
|
25 May 2022 |
Author responded |
Author comments - Yifan Zhai
|
Resubmission - Version 5 |
25 May 2022 |
Submitted |
Manuscript version 5
|
26 May 2022 |
Author responded |
Author comments - Yifan Zhai
|
Resubmission - Version 6 |
26 May 2022 |
Submitted |
Manuscript version 6
|
Publishing |
31 May 2022 |
Editorially accepted |
|
11 Jul 2022 |
Article published |
10.1186/s12885-022-09799-4
|
Learn about peer review